Cargando…
Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
BACKGROUND: Total Marrow and Lymphoid Irradiation (TMLI) is a promising component of the preparative regimen for hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Extramedullary (EM) relapse after TMLI is comparable to TBI a...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660291/ https://www.ncbi.nlm.nih.gov/pubmed/36387179 http://dx.doi.org/10.3389/fonc.2022.1017355 |
_version_ | 1784830390048915456 |
---|---|
author | Ladbury, Colton Semwal, Hemal Hong, Daniel Yang, Dongyun Hao, Claire Han, Chunhui Liu, An Marcucci, Guido Rosenthal, Joseph Hui, Susanta Salhotra, Amandeep Ali, Haris Nakamura, Ryotaro Stein, Anthony Al Malki, Monzr Wong, Jeffrey Y. C. Dandapani, Savita |
author_facet | Ladbury, Colton Semwal, Hemal Hong, Daniel Yang, Dongyun Hao, Claire Han, Chunhui Liu, An Marcucci, Guido Rosenthal, Joseph Hui, Susanta Salhotra, Amandeep Ali, Haris Nakamura, Ryotaro Stein, Anthony Al Malki, Monzr Wong, Jeffrey Y. C. Dandapani, Savita |
author_sort | Ladbury, Colton |
collection | PubMed |
description | BACKGROUND: Total Marrow and Lymphoid Irradiation (TMLI) is a promising component of the preparative regimen for hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Extramedullary (EM) relapse after TMLI is comparable to TBI and non-TBI conditioning regimens. This study evaluates outcomes of patients treated with radiotherapy (RT) with EM relapse previously treated with TMLI. METHODS: A retrospective analysis of five prospective TMLI trials was performed. TMLI targeted bones and major lymphoid tissues using image-guided tomotherapy, with total dose ranging from 12 to 20 Gy. EM recurrences were treated at the discretion of the hematologist and radiation oncologist using RT ± chemotherapy. Descriptive statistics and survival analysis were then performed on this cohort. RESULTS: In total, 254 patients with refractory or relapsed AML or ALL were treated with TMLI at our institution. Twenty-one patients were identified as receiving at least one subsequent course of radiation. A total of 67 relapse sites (median=2 sites/patient, range=1-16) were treated. Eleven relapsed patients were initially treated with curative intent. Following the initial course of subsequent RT, 1-year, 3-year and 5-year estimates of OS were 47.6%, 32.7% and 16.3%, respectively. OS was significantly better in patients treated with curative intent, with median OS of 50.7 months vs 1.6 months (p<0.001). 1-year, 3-year and 5-year estimates of PFS were 23.8%, 14.3% and 14.3%, respectively. PFS was significantly better in patients treated with curative intent, with median PFS of 6.6 months vs 1.3 months (p<0.001). Following RT, 86.6% of the sites had durable local control. CONCLUSIONS: RT is an effective modality to treat EM relapse in patients with acute leukemia who relapse after HCT achieving high levels of local control. In patients with limited relapse amenable to curative intent, radiation confers favorable long-term survival. Radiation as salvage treatment for EM relapse after HCT warrants further evaluation. |
format | Online Article Text |
id | pubmed-9660291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96602912022-11-15 Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia Ladbury, Colton Semwal, Hemal Hong, Daniel Yang, Dongyun Hao, Claire Han, Chunhui Liu, An Marcucci, Guido Rosenthal, Joseph Hui, Susanta Salhotra, Amandeep Ali, Haris Nakamura, Ryotaro Stein, Anthony Al Malki, Monzr Wong, Jeffrey Y. C. Dandapani, Savita Front Oncol Oncology BACKGROUND: Total Marrow and Lymphoid Irradiation (TMLI) is a promising component of the preparative regimen for hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Extramedullary (EM) relapse after TMLI is comparable to TBI and non-TBI conditioning regimens. This study evaluates outcomes of patients treated with radiotherapy (RT) with EM relapse previously treated with TMLI. METHODS: A retrospective analysis of five prospective TMLI trials was performed. TMLI targeted bones and major lymphoid tissues using image-guided tomotherapy, with total dose ranging from 12 to 20 Gy. EM recurrences were treated at the discretion of the hematologist and radiation oncologist using RT ± chemotherapy. Descriptive statistics and survival analysis were then performed on this cohort. RESULTS: In total, 254 patients with refractory or relapsed AML or ALL were treated with TMLI at our institution. Twenty-one patients were identified as receiving at least one subsequent course of radiation. A total of 67 relapse sites (median=2 sites/patient, range=1-16) were treated. Eleven relapsed patients were initially treated with curative intent. Following the initial course of subsequent RT, 1-year, 3-year and 5-year estimates of OS were 47.6%, 32.7% and 16.3%, respectively. OS was significantly better in patients treated with curative intent, with median OS of 50.7 months vs 1.6 months (p<0.001). 1-year, 3-year and 5-year estimates of PFS were 23.8%, 14.3% and 14.3%, respectively. PFS was significantly better in patients treated with curative intent, with median PFS of 6.6 months vs 1.3 months (p<0.001). Following RT, 86.6% of the sites had durable local control. CONCLUSIONS: RT is an effective modality to treat EM relapse in patients with acute leukemia who relapse after HCT achieving high levels of local control. In patients with limited relapse amenable to curative intent, radiation confers favorable long-term survival. Radiation as salvage treatment for EM relapse after HCT warrants further evaluation. Frontiers Media S.A. 2022-10-31 /pmc/articles/PMC9660291/ /pubmed/36387179 http://dx.doi.org/10.3389/fonc.2022.1017355 Text en Copyright © 2022 Ladbury, Semwal, Hong, Yang, Hao, Han, Liu, Marcucci, Rosenthal, Hui, Salhotra, Ali, Nakamura, Stein, Al Malki, Wong and Dandapani https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ladbury, Colton Semwal, Hemal Hong, Daniel Yang, Dongyun Hao, Claire Han, Chunhui Liu, An Marcucci, Guido Rosenthal, Joseph Hui, Susanta Salhotra, Amandeep Ali, Haris Nakamura, Ryotaro Stein, Anthony Al Malki, Monzr Wong, Jeffrey Y. C. Dandapani, Savita Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia |
title | Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia |
title_full | Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia |
title_fullStr | Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia |
title_full_unstemmed | Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia |
title_short | Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia |
title_sort | role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660291/ https://www.ncbi.nlm.nih.gov/pubmed/36387179 http://dx.doi.org/10.3389/fonc.2022.1017355 |
work_keys_str_mv | AT ladburycolton roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT semwalhemal roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT hongdaniel roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT yangdongyun roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT haoclaire roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT hanchunhui roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT liuan roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT marcucciguido roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT rosenthaljoseph roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT huisusanta roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT salhotraamandeep roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT aliharis roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT nakamuraryotaro roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT steinanthony roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT almalkimonzr roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT wongjeffreyyc roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia AT dandapanisavita roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia |